Ravulizumab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 404 publications

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: March 05, 2026

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Journal: Internal medicine (Tokyo, Japan)

Published: February 23, 2026

Use of ravulizumab in a pregnant patient with PNH: case-based insights.

Use of ravulizumab in a pregnant patient with PNH: case-based insights.

Journal: Clinical advances in hematology & oncology : H&O

Published: February 20, 2026

Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.

Diverticular Perforation with Normal C-reactive Protein in a Patient with Neuromyelitis Optica Spectrum Disorder Receiving Satralizumab.

Journal: Internal medicine (Tokyo, Japan)

Published: February 11, 2026

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: February 11, 2026

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Practical Considerations for Infection Prevention with the Clinical Use of Complement Inhibitors.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: February 06, 2026

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Real-World Effectiveness of Ravulizumab Among C5 Inhibitor-Naive Patients With Atypical Hemolytic Uremic Syndrome: A Physician Panel-Based Chart Review (aHUS IMPACT Study).

Journal: Kidney medicine

Published: February 03, 2026

Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance.

Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: January 21, 2026

Nummular eczema onset in an AQP4-IgG-positive NMOSD patient treated with ravulizumab.

Nummular eczema onset in an AQP4-IgG-positive NMOSD patient treated with ravulizumab.

Journal: Acta neurologica Belgica

Published: January 12, 2026

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: January 12, 2026

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Journal: Journal of medical economics

Published: January 10, 2026

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Crovalimab Rescue Therapy in a Case With Genetic Complement Mediated Thrombotic Microangiopathy.

Journal: Kidney medicine

Published: January 08, 2026

Showing 1-12 of 404

Last Updated: 04/28/2026